EricScottSchaeferMD

Oncology • Fayetteville, AR

Physician

Join to view full profile

Dr. Schaefer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schaefer's full profile

Already have an account?

Office
3232 N Northhills Blvd
Fayetteville, AR 72703
Phone+1 479-587-1700

Fax+1 479-587-1366

Education & Training

Wake Forest University Baptist Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 2003 - 2006
The University of Toledo College of MedicineClass of 2003

Certifications & Licensure

AR State Medical License 2009 - 2026
NC State Medical License 2003 - 2013
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2012

Clinical Trials

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
Completed
Phase 3
Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer Start of enrollment: 2015 Aug 06
Completed
Phase 2
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study Start of enrollment: 2015 Dec 11
Active, not recruiting
Phase 4
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Start of enrollment: 2016 May 11
Completed
Phase 2
The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread Start of enrollment: 2018 Nov 28
Completed
Phase 2
A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer Start of enrollment: 2019 Jul 16
Completed
Phase 1
This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. Start of enrollment: 2019 Nov 05
Terminated
Phase 2
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Start of enrollment: 2022 Dec 14
Terminated
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.
Armando Santoro, Garrido Pilar, Daniel S W Tan, Jon Zugazagoitia, Frances A Shepherd
BMC Cancer. 2024-11-21
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer.
Daniel Morgensztern, Neal Ready, Melissa L Johnson, Afshin Dowlati, Noura Choudhury
Clinical Cancer Research. 2024-11-15
1 citations
Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.
Armando Santoro, Garrido Pilar, Daniel S W Tan, Jon Zugazagoitia, Frances A Shepherd
BMC Cancer. 2024-10-24

Press Mentions

Biodesix Releases New Data at AACR on Proteomic Profiling to Help Guide Physician Treatment Strategies for NSCLC PatientsApril 10th, 2021